NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for TARA-002 for the treatment of Lymphatic Malformations (LMs). TARA-002 is an investigational cell-based therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for the treatment of LMs. LMs are rare, typically congenital, malformations of the lymphatic vasculature.
"Receipt of Rare Pediatric Disease designation from the FDA for TARA-002 in LMs further underscores the significant unmet medical need for the children that are affected by this rare and serious disease," said Jesse Shefferman, Chief Executive Officer ofProtara Therapeutics. "We are encouraged about the potential of TARA-002 to enhance the treatment paradigm of LMs for this underserved population, and we look forward to working with the agency to determine next steps for the program in the coming months."